Organon & Co. (NYSE:OGN) Shares Bought by Jones Financial Companies Lllp

Jones Financial Companies Lllp raised its stake in Organon & Co. (NYSE:OGN) by 1,795.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,550 shares of the company’s stock after acquiring an additional 4,310 shares during the period. Jones Financial Companies Lllp’s holdings in Organon & Co. were worth $68,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of OGN. Pacer Advisors Inc. boosted its stake in Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after acquiring an additional 11,140,388 shares in the last quarter. Weiss Asset Management LP acquired a new stake in shares of Organon & Co. during the third quarter worth about $32,966,000. Jacobs Levy Equity Management Inc. boosted its stake in shares of Organon & Co. by 303.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock worth $23,762,000 after buying an additional 934,505 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Organon & Co. by 35.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock worth $63,570,000 after buying an additional 875,128 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Organon & Co. by 191.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 760,807 shares of the company’s stock worth $11,382,000 after buying an additional 499,616 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Trading Up 2.1 %

NYSE OGN opened at $15.63 on Tuesday. The stock has a market capitalization of $4.03 billion, a P/E ratio of 4.69, a P/E/G ratio of 0.90 and a beta of 0.76. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The firm has a 50-day moving average price of $15.46 and a 200 day moving average price of $16.60. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Equities research analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.17%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Wall Street Analyst Weigh In

OGN has been the subject of several recent research reports. Barclays decreased their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Morgan Stanley decreased their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, February 14th. Finally, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.